Clinical Trials Logo

Clinical Trial Summary

On 12 January 2020, the World Health Organization (WHO) confirmed that a novel coronavirus was the cause of a respiratory illness in a cluster of people in Wuhan City, Hubei Province, China, which was reported to the WHO on 31 December 2019.

There is evidence of a high prevalence of psychiatric comorbidities in Fibromyalgia (FM )(especially depression, anxiety, post-traumatic stress disorder), which are associated with a worse clinical profile.

In these challenging times of COVID-19, anxiety increased among the general population. Fibromyalgia patients are more at risk of developing anxiety in these difficult times. This might result in more frequent visits to the rheumatology clinics with an exacerbation of their chronic pain syndrome.


Clinical Trial Description

The first confirmed case relating to the COVID-19 pandemic in the United Arab Emirates was announced on 29 January 2020.

On March 11, the World Health Organization (WHO) declared the global outbreak a pandemic. Many measures have been taken by the UAE government since the COVID-19 outbreak started hitting the region. From Mid March, the UAE had advised all citizens to restrict themselves to essential travel only and had implemented a curfew between 8 pm and 6 am every day starting from the end of March. On April 5th, UAE imposed a two-week lockdown to contain the COVID-19 pandemic and announced there will be disinfection drives.

Many awareness campaigns were initiated by rheumatologists through different media channels advising patients with rheumatic diseases to avoid clinics and hospitals unless they have an emergency. Some healthcare facilities started telemedicine services including rheumatology outpatient clinics. However, most of the clinics and hospitals have maintained open rheumatology clinics aiming to manage emergency cases.

Fibromyalgia (FM) is a chronic disorder characterized by widespread and chronic musculoskeletal pain and other frequent syndromes such as chronic fatigue sleep disturbance, cognitive impairment, irritable bowel disease, depression, and anxiety.

There is evidence of a high prevalence of psychiatric comorbidities in FM (especially depression, anxiety, post-traumatic stress disorder), which are associated with a worse clinical profile.

In these challenging times of COVID-19, anxiety increased among the general population. Fibromyalgia patients are more at risk of developing anxiety in these difficult times. This might result in more frequent visits to the rheumatology clinics with an exacerbation of their chronic pain syndrome. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04422522
Study type Observational
Source Al-Azhar University
Contact
Status Active, not recruiting
Phase
Start date March 15, 2020
Completion date June 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT03149198 - Mat Pilates Method in the Treatment of Women With Fibromyalgia N/A
Completed NCT00965081 - A Study for Adult Patients With Fibromyalgia Phase 4
Enrolling by invitation NCT06100926 - Effectiveness of Virtual Reality (VR) in Non-oncologic Chronic Musculoskeletal Pain N/A
Recruiting NCT05068791 - Psilocybin-facilitated Treatment for Chronic Pain Early Phase 1
Recruiting NCT05801497 - Balneotherapy in Primary Fibromyalgia
Completed NCT05361577 - Exopulse Mollii Suit and Fibromyalgia N/A
Recruiting NCT05754190 - Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
Recruiting NCT05941780 - Pain Phenotypes in Patients With Fibromyalgia Syndrome
Completed NCT04771260 - Understanding Health Services Delivery for Fibromyalgia
Active, not recruiting NCT04690400 - Telehealth Stretching Exercise Program for Women With Fibromyalgia During the Covid-19 Pandemic N/A
Recruiting NCT05644054 - The Impact of THC on Pain Modulation in Fibromyalgia N/A
Enrolling by invitation NCT04098757 - Fibromyalgia Different Approaches: Acupuncture vs Migratens
Completed NCT01697254 - The CARRA Registry N/A
Completed NCT00678691 - An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Phase 4
Recruiting NCT04832100 - Bio-significance of LPC16:0 in Fibromyalgia
Not yet recruiting NCT05688787 - Efficacy of Perineural Injection Therapy in Primary Fibromyalgia N/A
Completed NCT03905486 - Efficacy of Pregabalin Versus Combined Pregabalin and Milnacipran in Fibromyalgia. N/A